The Impact of Bariatric Surgery on Nonalcoholic Steatohepatitis

 

 Buy Article Permissions and Reprints

Abstract

Nonalcoholic steatohepatitis (NASH) is a stage of nonalcoholic fatty liver disease (NAFLD), and in most patients, is associated with obesity and the metabolic syndrome. The current best treatment of NAFLD and NASH is weight reduction with the current options being life style modifications, with or without pharmaceuticals, and bariatric surgery. Bariatric surgery is an effective treatment option for individuals who are severely obese (body mass index ≥ 35 kg/m²), and provides for long-term weight loss and resolution of obesity-associated diseases in most patients. Regression and/or histologic improvement of NASH have been documented after bariatric surgery. We review the available literature reporting on the impact of the various bariatric surgery techniques on NASH.

• References

• 1 Kowdley KV, Caldwell S. Nonalcoholic steatohepatitis: a twenty-first century epidemic?. J Clin Gastroenterol 2006; 40 (Suppl 1) S2-S4
  PubMedGoogle Scholar
• 2 McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006; 40 (Suppl 1) S17-S29
  PubMedGoogle Scholar
• 3 Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology 2004; 40 (2) 475-483
  CrossrefPubMedGoogle Scholar
• 4 McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8 (3) 521-533 , viii
  CrossrefPubMedGoogle Scholar
• 5 Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116 (6) 1413-1419
  CrossrefPubMedGoogle Scholar
• 6 Liou I, Kowdley KV. Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006; 40 (Suppl 1) S11-S16
  PubMedGoogle Scholar
• 7 Maheshwari A, Thuluvath PJ. Cryptogenic cirrhosis and NAFLD: are they related?. Am J Gastroenterol 2006; 101 (3) 664-668
  CrossrefPubMedGoogle Scholar
• 8 Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2004; 40 (4) 578-584
  CrossrefPubMedGoogle Scholar
• 9 Hui JM, Kench JG, Chitturi S , et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003; 38 (2) 420-427
  PubMedGoogle Scholar
• 10 Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346 (16) 1221-1231
  CrossrefPubMedGoogle Scholar
• 11 Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40 (Suppl 1) S5-S10
  PubMedGoogle Scholar
• 12 Ong JP, Elariny H, Collantes R , et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 2005; 15 (3) 310-315
  CrossrefPubMedGoogle Scholar
• 13 Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005; 42 (5) 987-1000
  CrossrefPubMedGoogle Scholar
• 14 Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21 (1) 27-41
  Article in Thieme ConnectPubMedGoogle Scholar
• 15 Neuschwander-Tetri BA. Evolving pathophysiologic concepts in nonalcoholic steatohepatitis. Curr Gastroenterol Rep 2002; 4 (1) 31-36
  CrossrefPubMedGoogle Scholar
• 16 Campos GM, Bambha K, Vittinghoff E , et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 2008; 47 (6) 1916-1923
  CrossrefPubMedGoogle Scholar
• 17 Anty R, Iannelli A, Patouraux S , et al. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther 2010; 32 (11–12) 1315-1322
  CrossrefPubMedGoogle Scholar
• 18 Sumida Y, Yoneda M, Hyogo H , et al; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 2011; 46 (2) 257-268
  CrossrefPubMedGoogle Scholar
• 19 Lam BP, Younossi ZM. Treatment regimens for non-alcoholic fatty liver disease. Ann Hepatol 2009; 8 (Suppl 1) S51-S59
  PubMedGoogle Scholar
• 20 Rafiq N, Younossi ZM. Effects of weight loss on nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28 (4) 427-433
  Article in Thieme ConnectPubMedGoogle Scholar
• 21 Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010; (1) CD007340
  PubMedGoogle Scholar
• 22 Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 2010; 11 (6) 430-445
  PubMedGoogle Scholar
• 23 Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009; 49 (1) 306-317
  CrossrefPubMedGoogle Scholar
• 24 Steinbrook R. Surgery for severe obesity. N Engl J Med 2004; 350 (11) 1075-1079
  CrossrefPubMedGoogle Scholar
• 25 Padwal R, Klarenbach S, Wiebe N , et al. Bariatric surgery: a systematic review of the clinical and economic evidence. J Gen Intern Med 2011; 26 (10) 1183-1194
  CrossrefPubMedGoogle Scholar
• 26 Ali MR, Fuller WD, Choi MP, Wolfe BM. Bariatric surgical outcomes. Surg Clin North Am 2005; 85 (4) 835-852 , vii
  CrossrefPubMedGoogle Scholar
• 27 Buchwald H, Estok R, Fahrbach K, Banel D, Sledge I. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery 2007; 142 (4) 621-632 , discussion 632–635
  CrossrefPubMedGoogle Scholar
• 28 Campos GM, Ciovica R, Rogers SJ , et al. Spectrum and risk factors of complications after gastric bypass. Arch Surg 2007; 142 (10) 969-975 , discussion 976
  CrossrefPubMedGoogle Scholar
• 29 Salem L, Jensen CC, Flum DR. Are bariatric surgical outcomes worth their cost? A systematic review. J Am Coll Surg 2005; 200 (2) 270-278
  CrossrefPubMedGoogle Scholar
• 30 Buchwald H, Estok R, Fahrbach K , et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122 (3) 248-256 , e5
  CrossrefPubMedGoogle Scholar
• 31 Nguyen NT, Goldman C, Rosenquist CJ , et al. Laparoscopic versus open gastric bypass: a randomized study of outcomes, quality of life, and costs. Ann Surg 2001; 234 (3) 279-289 , discussion 289–291
  CrossrefPubMedGoogle Scholar
• 32 Karlsson J, Taft C, Rydén A, Sjöström L, Sullivan M. Ten-year trends in health-related quality of life after surgical and conventional treatment for severe obesity: the SOS intervention study. Int J Obes (Lond) 2007; 31 (8) 1248-1261
  CrossrefPubMedGoogle Scholar
• 33 Buchwald H, Avidor Y, Braunwald E , et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292 (14) 1724-1737
  CrossrefPubMedGoogle Scholar
• 34 Sjöström L, Lindroos AK, Peltonen M , et al; Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351 (26) 2683-2693
  CrossrefPubMedGoogle Scholar
• 35 Christou NV, Sampalis JS, Liberman M , et al. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg 2004; 240 (3) 416-423 , discussion 423–424
  CrossrefPubMedGoogle Scholar
• 36 Adams TD, Gress RE, Smith SC , et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357 (8) 753-761
  CrossrefPubMedGoogle Scholar
• 37 Sjöström L, Narbro K, Sjöström CD , et al; Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357 (8) 741-752
  CrossrefPubMedGoogle Scholar
• 38 Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol 1995; 104 (1) 23-31
  PubMedGoogle Scholar
• 39 Clark JM, Alkhuraishi AR, Solga SF, Alli P, Diehl AM, Magnuson TH. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res 2005; 13 (7) 1180-1186
  CrossrefPubMedGoogle Scholar
• 40 Mattar SG, Velcu LM, Rabinovitz M , et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005; 242 (4) 610-617 , discussion 618–620
  PubMedGoogle Scholar
• 41 Mottin CC, Moretto M, Padoin AV , et al. Histological behavior of hepatic steatosis in morbidly obese patients after weight loss induced by bariatric surgery. Obes Surg 2005; 15 (6) 788-793
  CrossrefPubMedGoogle Scholar
• 42 Klein S, Mittendorfer B, Eagon JC , et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 2006; 130 (6) 1564-1572
  CrossrefPubMedGoogle Scholar
• 43 Barker KB, Palekar NA, Bowers SP, Goldberg JE, Pulcini JP, Harrison SA. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 2006; 101 (2) 368-373
  CrossrefPubMedGoogle Scholar
• 44 Csendes A, Smok G, Burgos AM. Histological findings in the liver before and after gastric bypass. Obes Surg 2006; 16 (5) 607-611
  CrossrefPubMedGoogle Scholar
• 45 de Almeida SR, Rocha PR, Sanches MD , et al. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes Surg 2006; 16 (3) 270-278
  CrossrefPubMedGoogle Scholar
• 46 Furuya Jr CK, de Oliveira CP, de Mello ES , et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol 2007; 22 (4) 510-514
  CrossrefPubMedGoogle Scholar
• 47 Liu X, Lazenby AJ, Clements RH, Jhala N, Abrams GA. Resolution of nonalcoholic steatohepatitis after gastric bypass surgery. Obes Surg 2007; 17 (4) 486-492
  CrossrefPubMedGoogle Scholar
• 48 Weiner RA. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Dig Dis 2010; 28 (1) 274-279
  CrossrefPubMedGoogle Scholar
• 49 Moretto M, Kupski C, da Silva VD, Padoin AV, Mottin CC. Effect of bariatric surgery on liver fibrosis. Obes Surg 2011;
  PubMedGoogle Scholar
• 50 Dixon JB, Bhathal PS, O'Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg 2006; 16 (10) 1278-1286
  CrossrefPubMedGoogle Scholar
• 51 Mathurin P, Hollebecque A, Arnalsteen L , et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009; 137 (2) 532-540
  CrossrefPubMedGoogle Scholar
• 52 Kral JG, Thung SN, Biron S , et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004; 135 (1) 48-58
  CrossrefPubMedGoogle Scholar
• 53 Keshishian A, Zahriya K, Willes EB. Duodenal switch has no detrimental effects on hepatic function and improves hepatic steatohepatitis after 6 months. Obes Surg 2005; 15 (10) 1418-1423
  CrossrefPubMedGoogle Scholar
• 54 Ranløv I, Hardt F. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion 1990; 47 (4) 208-214
  CrossrefPubMedGoogle Scholar
• 55 Luyckx FH, Desaive C, Thiry A , et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998; 22 (3) 222-226
  CrossrefPubMedGoogle Scholar
• 56 Stratopoulos C, Papakonstantinou A, Terzis I , et al. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obes Surg 2005; 15 (8) 1154-1160
  CrossrefPubMedGoogle Scholar
• 57 Jaskiewicz K, Raczynska S, Rzepko R, Sledziński Z. Nonalcoholic fatty liver disease treated by gastroplasty. Dig Dis Sci 2006; 51 (1) 21-26
  CrossrefPubMedGoogle Scholar
• 58 Gastrointestinal surgery for severe obesity. NIH consensus development conference, March 25-7,1991. Nutrition 1996; 12 (6) 397-404
  CrossrefPubMedGoogle Scholar
• 59 U.S. Food and Drug Administration. FDA expands use of banding system for weight loss. February 16, 2011 News release. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm245617.htm . Accessed December 4, 2011
  PubMedGoogle Scholar
• 60 Gould J, Ellsmere J, Fanelli R , et al. Panel report: best practices for the surgical treatment of obesity. Surg Endosc 2011; 25 (6) 1730-1740
  CrossrefPubMedGoogle Scholar
• 61 Campos GM, Rabl C, Roll GR , et al. Better weight loss, resolution of diabetes, and quality of life for laparoscopic gastric bypass vs banding: results of a 2-cohort pair-matched study. Arch Surg 2011; 146 (2) 149-155
  CrossrefPubMedGoogle Scholar
• 62 Flum DR, Belle SH, King WC , et al; Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009; 361 (5) 445-454
  CrossrefPubMedGoogle Scholar
• 63 Tice JA, Karliner L, Walsh J, Petersen AJ, Feldman MD. Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures. Am J Med 2008; 121 (10) 885-893
  CrossrefPubMedGoogle Scholar
• 64 Vetter ML, Vinnard CL, Wadden TA. Perioperative safety and bariatric surgery. N Engl J Med 2009; 361 (19) 1910 , author reply 1911
  CrossrefPubMedGoogle Scholar
• 65 Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 1999; 149 (11) 981-983
  CrossrefPubMedGoogle Scholar
• 66 DeMaria EJ. Bariatric surgery for morbid obesity. N Engl J Med 2007; 356 (21) 2176-2183
  CrossrefPubMedGoogle Scholar
• 67 Buchwald H ; Consensus Conference Panel. Consensus conference statement bariatric surgery for morbid obesity: health implications for patients, health professionals, and third-party payers. Surg Obes Relat Dis 2005; 1 (3) 371-381
  CrossrefPubMedGoogle Scholar
• 68 Cunneen SA. Review of meta-analytic comparisons of bariatric surgery with a focus on laparoscopic adjustable gastric banding. Surg Obes Relat Dis 2008; 4 (3, Suppl) S47-S55
  CrossrefPubMedGoogle Scholar
• 69 Gagner M, Milone L, Yung E, Broseus A, Gumbs AA. Causes of early mortality after laparoscopic adjustable gastric banding. J Am Coll Surg 2008; 206 (4) 664-669
  CrossrefPubMedGoogle Scholar
• 70 Buchwald H, Williams SE. Bariatric surgery training in the United States. Surg Obes Relat Dis 2006; 2 (1) 52-55 , discussion 55–56
  CrossrefPubMedGoogle Scholar
• 71 Himpens J, Cadière GB, Bazi M, Vouche M, Cadière B, Dapri G. Long-term outcomes of laparoscopic adjustable gastric banding. Arch Surg 2011; 146 (7) 802-807
  CrossrefPubMedGoogle Scholar
• 72 Nguyen NT, Sloan J, Nguyen XM. Laparoscopic gastric bypass or gastric banding: which operation is best?. Adv Surg 2010; 44: 49-57
  CrossrefPubMedGoogle Scholar
• 73 Colquitt JL, Picot J, Loveman E, Clegg AJ. Surgery for obesity. Cochrane Database Syst Rev 2009; (2) CD003641
  PubMedGoogle Scholar
• 74 Kim S, Richards WO. Long-term follow-up of the metabolic profiles in obese patients with type 2 diabetes mellitus after Roux-en-Y gastric bypass. Ann Surg 2010; 251 (6) 1049-1055
  CrossrefPubMedGoogle Scholar
• 75 de Freitas AC, Campos AC, Coelho JC. The impact of bariatric surgery on nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 2008; 11 (3) 267-274
  CrossrefPubMedGoogle Scholar
• 76 Verna EC, Berk PD. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery. Semin Liver Dis 2008; 28 (4) 407-426
  Article in Thieme ConnectPubMedGoogle Scholar
• 77 Kashi MR, Torres DM, Harrison SA. Current and emerging therapies in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28 (4) 396-406
  Article in Thieme ConnectPubMedGoogle Scholar
• 78 Grimm IS, Schindler W, Haluszka O. Steatohepatitis and fatal hepatic failure after biliopancreatic diversion. Am J Gastroenterol 1992; 87 (6) 775-779
  PubMedGoogle Scholar
• 79 Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004; 39 (6) 1647-1654
  CrossrefPubMedGoogle Scholar
• 80 Promrat K, Kleiner DE, Niemeier HM , et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51 (1) 121-129
  CrossrefPubMedGoogle Scholar
• 81 Campos GM, Rabl C, Peeva S , et al. Improvement in peripheral glucose uptake after gastric bypass surgery is observed only after substantial weight loss has occurred and correlates with the magnitude of weight lost. J Gastrointest Surg 2010; 14 (1) 15-23
  CrossrefPubMedGoogle Scholar
• 82 Peterli R, Wölnerhanssen B, Peters T , et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg 2009; 250 (2) 234-241
  CrossrefPubMedGoogle Scholar
• 83 Lee WJ, Chong K, Ser KH , et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg 2011; 146 (2) 143-148
  CrossrefPubMedGoogle Scholar
• 84 le Roux CW, Welbourn R, Werling M , et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007; 246 (5) 780-785
  CrossrefPubMedGoogle Scholar
• 85 Small CJ, Bloom SR. Gut hormones as peripheral anti-obesity targets. Curr Drug Targets CNS Neurol Disord 2004; 3 (5) 379-388
  CrossrefPubMedGoogle Scholar
• 86 Patriti A, Facchiano E, Sanna A, Gullà N, Donini A. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Obes Surg 2004; 14 (6) 840-848
  CrossrefPubMedGoogle Scholar
• 87 Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 2007; 3 (6) 597-601
  CrossrefPubMedGoogle Scholar
• 88 Baggio LL, Drucker DJ. Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2. Best Pract Res Clin Endocrinol Metab 2004; 18 (4) 531-554
  CrossrefPubMedGoogle Scholar
• 89 Rubino F, Gagner M, Gentileschi P , et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 2004; 240 (2) 236-242
  CrossrefPubMedGoogle Scholar
• 90 Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132 (6) 2131-2157
  CrossrefPubMedGoogle Scholar
• 91 Pedersen J, Holst JJ. Glucagon like-peptide 1 receptor and the liver. Liver Int 2011; 31 (9) 1243-1245
  CrossrefPubMedGoogle Scholar
• 92 Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996; 137 (7) 2968-2978
  CrossrefPubMedGoogle Scholar
• 93 Klonoff DC, Buse JB, Nielsen LL , et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24 (1) 275-286
  CrossrefPubMedGoogle Scholar
• 94 Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006; 43 (1) 173-181
  CrossrefPubMedGoogle Scholar
• 95 Gupta NA, Mells J, Dunham RM , et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010; 51 (5) 1584-1592
  CrossrefPubMedGoogle Scholar
• 96 Svegliati-Baroni G, Saccomanno S, Rychlicki C , et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 2011; 31 (9) 1285-1297
  CrossrefPubMedGoogle Scholar
• 97 Neary NM, Small CJ, Bloom SR. Gut and mind. Gut 2003; 52 (7) 918-921
  CrossrefPubMedGoogle Scholar
• 98 Batterham RL, Cowley MA, Small CJ , et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418 (6898) 650-654
  CrossrefPubMedGoogle Scholar
• 99 Batterham RL, Cohen MA, Ellis SM , et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349 (10) 941-948
  CrossrefPubMedGoogle Scholar
• 100 Date Y, Kojima M, Hosoda H , et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000; 141 (11) 4255-4261
  CrossrefPubMedGoogle Scholar
• 101 Cummings DE, Shannon MH. Roles for ghrelin in the regulation of appetite and body weight. Arch Surg 2003; 138 (4) 389-396
  CrossrefPubMedGoogle Scholar
• 102 Cummings DE, Clement K, Purnell JQ , et al. Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med 2002; 8 (7) 643-644
  CrossrefPubMedGoogle Scholar
• 103 Purnell JQ, Weigle DS, Breen P, Cummings DE. Ghrelin levels correlate with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or cortisol levels in humans. J Clin Endocrinol Metab 2003; 88 (12) 5747-5752
  CrossrefPubMedGoogle Scholar
• 104 Cummings DE, Weigle DS, Frayo RS , et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346 (21) 1623-1630
  CrossrefPubMedGoogle Scholar
• 105 Korner J, Bessler M, Cirilo LJ , et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 2005; 90 (1) 359-365
  CrossrefPubMedGoogle Scholar
• 106 Lin E, Gletsu N, Fugate K , et al. The effects of gastric surgery on systemic ghrelin levels in the morbidly obese. Arch Surg 2004; 139 (7) 780-784
  CrossrefPubMedGoogle Scholar
• 107 Hanusch-Enserer U, Cauza E, Brabant G , et al. Plasma ghrelin in obesity before and after weight loss after laparoscopical adjustable gastric banding. J Clin Endocrinol Metab 2004; 89 (7) 3352-3358
  CrossrefPubMedGoogle Scholar
• 108 Hanusch-Enserer U, Brabant G, Roden M. Ghrelin concentrations in morbidly obese patients after adjustable gastric banding. N Engl J Med 2003; 348 (21) 2159-2160
  PubMedGoogle Scholar
• 109 Stoeckli R, Chanda R, Langer I, Keller U. Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass. Obes Res 2004; 12 (2) 346-350
  CrossrefPubMedGoogle Scholar
• 110 Plum L, Ahmed L, Febres G , et al. Comparison of glucostatic parameters after hypocaloric diet or bariatric surgery and equivalent weight loss. Obesity (Silver Spring) 2011; 19 (11) 2149-2157
  CrossrefPubMedGoogle Scholar
• 111 Swarbrick MM, Austrheim-Smith IT, Stanhope KL , et al. Circulating concentrations of high-molecular-weight adiponectin are increased following Roux-en-Y gastric bypass surgery. Diabetologia 2006; 49 (11) 2552-2558
  CrossrefPubMedGoogle Scholar
• 112 Swarbrick MM, Stanhope KL, Austrheim-Smith IT , et al. Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery. Diabetologia 2008; 51 (10) 1901-1911
  CrossrefPubMedGoogle Scholar
• 113 Marantos G, Daskalakis M, Karkavitsas N, Matalliotakis I, Papadakis JA, Melissas J. Changes in metabolic profile and adipoinsular axis in morbidly obese premenopausal females treated with restrictive bariatric surgery. World J Surg 2011; 35 (9) 2022-2030
  CrossrefPubMedGoogle Scholar
• 114 Lima MM, Pareja JC, Alegre SM , et al. Acute effect of Roux-en-Y gastric bypass on whole-body insulin sensitivity: a study with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab 2010; 95 (8) 3871-3875
  CrossrefPubMedGoogle Scholar